老虎證券

BUZZ-RBC Capital Markets says Gilead's Yeztugo sales to beat Q3 estimates; shares up

Reuters
昨天
BUZZ-RBC Capital Markets says <a href="https://laohu8.com/S/GILD">Gilead</a>'s Yeztugo sales to beat Q3 estimates; shares up

** Shares of drugmaker Gilead GILD.O rise 5% to $123.58

** RBC Capital Markets estimates GILD's HIV prevention drug Yeztugo could beat consensus expectations in Q3, projecting sales of $45 million compared to the Street's $35 million, driven by switching demand and early uptake

** CVS's decision not to cover Yeztugo yet, along with formulary delays and continued use of generic Truvada, may limit near-term uptake, brokerage adds

** RBC Capital Markets expects a Q3 beat for GILD's HIV drug Biktarvy, but continues to monitor for any potential MFN impact longer term

** Company is expected to report Q3 earnings on October 30

** Including session moves, stock up 33.98% YTD

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10